Springboard Capital

AxoGen, Inc. is a company focused on developing and commercializing innovative solutions for the repair and regeneration of peripheral nerve injuries. Based in Alachua, Florida, and founded in 2002, AxoGen offers a range of products designed for effective surgical procedures, including the AVANCE Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. Additionally, it provides the Axotouch Two-Point Discriminator, a device used to assess the innervation density of skin. AxoGen's offerings are aimed at surgeons and healthcare providers, ensuring clinically and economically effective solutions for nerve repair. The company also has a strategic partnership with the American Tissue Services Foundation for tissue recovery and distributes its products across the United States and several international markets, including Canada, Germany, the United Kingdom, Spain, and South Korea.

Consolidated Asset Recovery Systems, Inc. is a software development company based in Raleigh, North Carolina, specializing in repossession management and marketing solutions for lenders, dealers, and recovery agents. Founded in 2005, the company has created the Internet Based Electronic Asset Management (IBEAM) technology to facilitate the tracking and recovery of assets. Their offerings include repossession management, electronic invoicing, skip tracing, audits, legal demand creation, and automated notifications. With a network of recovery agents across the United States, the company ensures compliance and quality in asset recovery services. Consolidated Asset Recovery Systems has experienced significant growth, positioning itself as a trusted partner for many service providers in the industry. Its commitment to transparency and adaptability allows lenders to manage their underperforming assets efficiently, supported by a comprehensive suite of software and services. As of April 2019, it operates as a subsidiary of Primeritus Financial Services, Inc.

Amulet Pharmaceuticals discovers and develops novel therapeutics using their NORTECHâ„¢ technology to address known liabilities of current therapies serving large unmet markets. Their lead program (AMU-301) treats diabetic gastroparesis an unmet complication of diabetes affecting over 3 million women in the United States.